Clinical Trials Browser

Phase 1/2 × sotigalimab × Dermatologic × Clear all

NCT02706353 2025-11-21

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

Phase 1/2 Terminated

34 enrolled 18 charts

Melanoma

NCT03123783 2023-12-26

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Phase 1/2 Completed

140 enrolled 16 charts

DermatologicThoracic

Lung Neoplasms, Melanoma, Neoplasms